Shukra Pharmaceuticals is currently trading at its upper limit of RS. 26.22, up by 0.51 points or 1.98% from its previous closing of RS. 25.71 on the BSE.

The stock opened at RS. 26.22 and recorded both its high and low at RS. 26.22. So far, 2,62,560 shares have been traded on the counter.

The BSE group 'XT' stock with a face value of RS. 1 touched a 52-week high of RS. 27.15 on March 5, 2025, and a 52-week low of RS. 5.75 on November 21, 2024. In the past week, the scrip’s high and low stood at RS. 26.22 and RS. 23.33, respectively. The company’s current market capitalization is RS. 1148.12 crore.

The promoter shareholding in the company stands at 50.96%, with institutions holding 0.11% and non-institutions 48.93%.

In a significant development, Shukra Pharmaceuticals has secured a prestigious Letter of Award (LoA) from HSCC (India), a Government of India enterprise under the Ministry of Housing & Urban Affairs, acting on behalf of the Ministry of External Affairs. The award, dated August 28, 2025, is for the supply of Medicines and Diagnostic Kits to Afghanistan (Technical Mission of India, Kabul).

The total contract value stands at RS. 24.06 crore, covering supply, packing, forwarding, insurance, and delivery at the consignee site in Afghanistan. This order further enhances the company’s international presence and underscores its ability to execute large-scale healthcare projects under Government of India-backed initiatives.

Shukra Pharmaceuticals continues to position itself as an ambitious, sustainability-driven organization with a strong portfolio of healthcare solutions.